Theratechnologies inc.
TSX : TH

Theratechnologies inc.

December 14, 2008 18:47 ET

Notice of Conference Call & Media Advisory: Theratechnologies reports 52-week confirmatory Phase 3 results

MONTREAL, QUEBEC--(Marketwire - Dec. 14, 2008) - Theratechnologies (TSX:TH) advises of an upcoming conference call and webcast to discuss the 52-week results of its confirmatory Phase 3 clinical trial, testing tesamorelin, in patients with HIV-associated lipodystrophy. The call will be moderated by Dr. Andrea Gilpin, Vice President, IR & Communications, at Theratechnologies. Mr. Yves Rosconi, President and CEO, Mr. Luc Tanguay, Senior Executive Vice President and CFO, Dr. Pierre Caudrelier, Chief Medical Officer and Dr. Christian Marsolais, Vice President, Clinical Research, will also be participating.

The conference call will take place tomorrow, December 15, 2008, at 8:00 a.m. Eastern Standard Time. Prior to the call, a press release will be issued around 7:00 a.m.

December 15, 2008 Conference Call and Webcast

For the conference call, interested participants are asked to dial the following numbers: 416-644-3418 or 1-800-732-9303 (toll free). Please call five minutes prior to the conference in order to ensure your participation. The webcast will be accessible at the following links: www.investorcalendar.com and www.theratech.com.

A replay of the conference call will be available from December 15, 2008 at 10:00 a.m. to December 22, 2008 at 11:59 p.m. at the following number: 416-640-1917, pass code 21292496# or 1-877-289-8525, code 2129496#. The webcast will be posted for 30 days at the following links: www.investorcalendar.com and www.theratech.com.

About Theratechnologies

Theratechnologies (TSX:TH) is a Canadian biopharmaceutical company that discovers innovative drug candidates in order to develop them and bring them to market. The Company targets unmet medical needs in financially attractive specialty markets. Its most advanced program is tesamorelin, which is concluding a confirmatory Phase 3 clinical trial for a serious metabolic disorder involving excess abdominal fat in HIV patients with lipodystrophy. The Company also has other projects at earlier stages of development.

Contact Information